Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Does donepezil improve symptoms in people with severe Alzheimer’s disease?
METHODS
Design:
Randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
Six months.
Setting:
Fifty nursing homes run by trained staff, Sweden; October 2002 to October 2004.
Patients:
248 nursing home residents aged over 50 years with possible or probable Alzheimer’s disease (DSM-IV and National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association criteria, and consistent CT or MRI scan) that was classed as severe (Mini-Mental State Examination score of 1–10), and with functional assessment staging rating of between 5 and 7c. Exclusions: inability to walk alone or with help; non-Alzheimer’s dementia; or primary psychiatric or neurological disorder.
Intervention:
Donepezil (5 mg/day for first 30 …
Footnotes
For correspondence: Professor Bengt Winblad, MD, Karolinska Institutet, Alzheimer’s Disease Research Center, Department of Neurotec, Division of Geriatric Medicine, Karolinska University Hospital, Huddinge, 14186 Stockholm, Sweden; bengt.winblad{at}ki.se
Source of funding: Pfizer Pharmaceuticals, Sweden.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.